P-396 Exploration of metabolomic markers for esophageal squamous cancer based on the Linxian Nutrition Intervention Trial population

According to the 2018 global cancer statistics, China accounts for more than 50% of new cases and mortality esophageal worldwide. Esophageal squamous carcinoma (ESCC) is predominant subtype in China, early diagnosis ESCC important because its poor prognosis high rate. Metabolomics has become an approach exploring biomarkers advantages easy sampling, dynamic real-time detection low bias results. Depending on population Linxian Nutrition Intervention Trial (NIT), we conducted a nested case-control study obtain differential metabolites by metabolomics explore possible prior development carcinoma.This was based cohort 1985, selected 30 patients with who developed disease after 2001,This 2001,and also matched healthy controls are still alive today according age (±3 years ) sex.During follow-up survey from autumn 1999 spring 2000, obtained plasma specimens above-mentioned subjects. Metabolomic assays were performed using LC-MS method metabolomic features analyzed. Metabolic pathways acquired Kyoto Encyclopedia Genes Genomes (KEGG) pathway database. There no differences baseline demographic information between group control groups, but there dietary preferences. The metabolome assay data stable, significant metabolite distribution two nine obtained, including glutamate, choline, lysophosphatidylcholine, ornithine. Patients have metabolic abnormalities onset disease. Certain substances volatile levels may be potential carcinoma. Choline metabolism biological indicator progression ESCC. authors.